^
    1d
    SCENT-3: Sintilimab, Chidamide, and Azacitidine for Untreated Stage I-II Extranodal NK/T-Cell Lymphoma (clinicaltrials.gov)
    P=N/A, N=30, Not yet recruiting, Sun Yat-sen University
    New trial
    |
    Tyvyt (sintilimab) • azacitidine • oxaliplatin • Epidaza (chidamide)
    1d
    A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC (clinicaltrials.gov)
    P2, N=118, Completed, Chipscreen Biosciences, Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • Epidaza (chidamide)
    2d
    SCREEN: Serplulimab, Chidamide, and Rituximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC/BCL2 Double-Expressor DLBCL (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, Sun Yat-sen University
    New P2 trial
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Epidaza (chidamide) • Hetronifly (serplulimab)
    7d
    HDAC inhibitor tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR-positive HER2-negative advanced breast cancer after CDK4/6 inhibitors treatment: clinical findings and exploratory circulating tumor cell and ctDNA biomarker analyses of a multicenter, phase 2 study (SYSUCC-020 trial). (PubMed, Signal Transduct Target Ther)
    This trial adopted a Simon two-stage design: eligible patients received tucidinostat plus metronomic capecitabine together with either an aromatase inhibitor (Cohort 1) or fulvestrant (Cohort 2), selected according to prior ET. In addition, exploratory analyses of biomarkers indicated that the baseline TP53 mutation status (Wild type vs. mutated, 7.64 months vs. 3.55 months) and circulating tumor cell (CTC) status (CTC-negative vs. CTC-positive, 7.59 months vs. 3.78 months) were associated with the median PFS. Our study demonstrated that tucidinostat combined with mCAP and ET is efficacious and well-tolerated in patients with HR-positive HER2-negative ABC previously treated with CDK4/6i.
    P2 data • Journal • Circulating tumor cells • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53)
    |
    HER-2 positive • TP53 mutation • HR positive • HER-2 negative • EGFR positive • HR positive + HER-2 negative
    |
    capecitabine • fulvestrant • Epidaza (chidamide)
    13d
    Design, synthesis and biological evaluation of Chidamide derivatives against breast cancer. (PubMed, Bioorg Med Chem Lett)
    In this study, we designed and synthesized a series of compounds derived from the histone deacetylase inhibitor (HDACi) Chidamide and the BET bromodomain inhibitor (+)-JQ-1. In the chicken embryo chorioallantoic membrane (CAM) model, 6e inhibited tumor growth and angiogenesis more effectively than chidamide. In summary, 6e demonstrates promising optimization potential as a lead compound for breast cancer therapy.
    Journal
    |
    ANXA5 (Annexin A5)
    |
    JQ-1 • Epidaza (chidamide)
    13d
    ABC-Maint: ABC Maintenance Therapy for AML (clinicaltrials.gov)
    P=N/A, N=104, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New trial
    |
    Venclexta (venetoclax) • azacitidine • Epidaza (chidamide)
    14d
    Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma (clinicaltrials.gov)
    P2, N=34, Recruiting, Sun Yat-sen University
    New P2 trial
    |
    Avastin (bevacizumab) • Tyvyt (sintilimab) • Epidaza (chidamide)
    14d
    DEB: Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL (clinicaltrials.gov)
    P3, N=423, Completed, Chipscreen Biosciences, Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Epidaza (chidamide)
    15d
    Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia (clinicaltrials.gov)
    P2, N=120, Recruiting, Chinese PLA General Hospital
    New P2 trial
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • Epidaza (chidamide) • daunorubicin • aclarubicin
    20d
    DEL-MRD-CHID: Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission (clinicaltrials.gov)
    P2, N=69, Not yet recruiting, Rong Tao
    New P2 trial • Minimal residual disease • Circulating tumor DNA
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Epidaza (chidamide)
    20d
    Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=200, Recruiting, Chinese PLA General Hospital | Trial completion date: Jan 2026 --> Jan 2030 | Trial primary completion date: Jan 2026 --> Jan 2029
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • Epidaza (chidamide) • fludarabine IV • aclarubicin
    21d
    Spatiotemporal Sequential Delivery of Chidamide Regulates Macrophage Reprogramming in Lymphoma Microenvironment Through HDACs-STAT3 Pathway. (PubMed, Adv Sci (Weinh))
    By targeted delivery to M2 macrophages, chidamide sufficiently inhibited HDACs, enhanced STAT3 acetylation, reprogrammed M2 proportion into M1 phenotype, and ultimately suppressed lymphoma growth in vivo. With reduced dosage and adverse reactions, our Chid@M2pep-EVs system provides a new translational strategy for treating refractory/relapsed lymphoma.
    Journal
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3)
    |
    Epidaza (chidamide)